• Mashup Score: 0

    Artesunate (ART) is a derivative of artemisinin. Compared with artemisinin, ART has excellent water solubility, high stability and oral bioavailability. In this review, the application of ART in classic autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and ulcerative colitis is summarized. ART exhibited similar or even better efficacy than other highly effective immunosuppressive agents, such as methotrexate and cyclophosphamide. In addition, ART exerts its pharmacological effects mainly by inhibiting the production of inflammatory factors, reactive oxygen species, autoantibodies and the migration of cells to reduce damage to tissues or organs. Moreover, ART widely affected the NF-κB, PI3K/Akt, JAK/STAT and MAPK pathways to exert pharmacological effects.

    Tweet Tweets with this article
    • Artesunate exerts its pharmacological effects mainly through #NF-κB, #PI3K/Akt, #JAK/ STAT, #MAPK pathways, and is also widely involved in the regulation of #Tcells, #Bcells, and #macrophages Read our latest review on the role of artesunate online: https://t.co/bItUGxD72S

  • Mashup Score: 0

    The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for the treatment of patients, 2 years of age and older, that have neurofibromatosis type 1 (NF1) with inoperable plexiform neurofibromas.

    Tweet Tweets with this article
    • The U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of patients with neurofibromatosis type 1 #NF) with inoperable plexiform neurofibromas. @AstraZeneca @US_FDA Astrazeneca FDA AstraZeneca https://t.co/ddx0NLYCmG